Proteomics

Dataset Information

0

Unveiling the inhibition mechanism of Clostridioides difficile by Bifidobacterium longum via multiomics approach


ABSTRACT: A major risk factor for Clostridioides difficile infection (CDI) is the perturbation of the gut microbiota by antibiotic administration, and antibiotic therapy, the standard treatment option for CDI, exacerbates the imbalance of the gut microbiota, leading to a very high recurrent CDI (rCDI) incidence rate. Therefore, CDI treatment based on live biotherapeutic products (LBPs) has recently emerged for long-term CDI management and preventive treatment However, there is limited research and understanding of how these LBPs improve CDI symptoms, which raises the need to elucidate the therapeutic mechanisms of LBPs. To fill this knowledge gap, here, we holistically analyzed and investigated the mechanisms involved in the inhibitory effect of probiotics on C. difficile at the molecular level through a multiomics approach on screened strain from probiotics that inhibit C. difficile growth. First, Bifidobacterium species were co-cultured with C. difficile, and B. longum was screened based on its ability to inhibit the growth of C. difficile. Then, the antimicrobial activity of B. longum against C. difficile was confirmed by spot-on-lawn assay and organic acid quantification. Next, we performed proteomic and metabolomic analysis on C. difficile co-cultured with B. longum, and observed physiological changes associated with the inhibition of C. difficile growth and toxin production. It was found that lactate produced by B. longum up-regulated the lactate dehydrogenase complex of C. difficile, leading to a decrease in intracellular ATP synthesis and a subsequent decrease in (deoxy)ribonucleoside triphosphate synthesis. Furthermore, proteinaceous stress induced by B. longum was also identified through the up-regulation of ribosomal proteins, molecular chaperones, and chaperonins, and the down-regulation of translation-related proteins. Finally, we found that B. longum suppressed butyrate metabolism and toxin production by producing and replenishing proline consumed by C. difficile. Therefore, this study will not only expand our understanding of the mechanisms of probiotics' inhibition of C. difficile, but also contribute to the development of LBPs based on molecular mechanisms for treating CDI.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Clostridioides Difficile Atcc 9689 = Dsm 1296

SUBMITTER: Sung-Hyun Jo  

LAB HEAD: Yun-Gon Kim

PROVIDER: PXD040738 | Pride | 2024-01-26

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
Co_culture_1.raw Raw
Co_culture_2.raw Raw
Co_culture_3.raw Raw
Co_culture_4.raw Raw
Control_CD_on_insert_1.raw Raw
Items per page:
1 - 5 of 14
altmetric image

Publications

Unveiling the inhibition mechanism of <i>Clostridioides difficile</i> by <i>Bifidobacterium longum via</i> multiomics approach.

Jo Sung-Hyun SH   Jeon Hyo-Jin HJ   Song Won-Suk WS   Lee Jae-Seung JS   Kwon Ji-Eun JE   Park Ji-Hyeon JH   Kim Ye-Rim YR   Kim Min-Gyu MG   Baek Ji-Hyun JH   Kwon Seo-Young SY   Kim Jae-Seok JS   Yang Yung-Hun YH   Kim Yun-Gon YG  

Frontiers in microbiology 20231108


Antibiotic-induced gut microbiota disruption constitutes a major risk factor for <i>Clostridioides difficile</i> infection (CDI). Further, antibiotic therapy, which is the standard treatment option for CDI, exacerbates gut microbiota imbalance, thereby causing high recurrent CDI incidence. Consequently, probiotic-based CDI treatment has emerged as a long-term management and preventive option. However, the mechanisms underlying the therapeutic effects of probiotics for CDI remain uninvestigated,  ...[more]

Similar Datasets

2019-05-09 | GSE122013 | GEO
2024-10-17 | GSE277716 | GEO
2019-10-24 | GSE135912 | GEO
2021-07-07 | GSE155167 | GEO
2022-03-24 | GSE199109 | GEO
2020-02-12 | GSE144291 | GEO
2010-08-07 | E-GEOD-18407 | biostudies-arrayexpress
2015-06-09 | ST000196 | MetabolomicsWorkbench
2024-02-04 | GSE254628 | GEO
2024-04-25 | GSE263792 | GEO